IL17A and rheumatoid arthritis: Therefore, recent clinical trials have demonstrated that increased cardiovascular mortality in patients with chronic inflammatory disease can be managed by targeting specific cytokines or activation of specific immune cells, e.g., in psoriasis the IL-17/IL-23 axis [40,41,42], in systemic lupus erythematodes IL-17A signaling [43], and in rheumatoid arthritis the IL-6, TNF-α, and IL-17A cascades [44,45].